Navigation Links
Governor Cuomo Announces Continued Growth at Roswell Park Cancer Institute with Regional Economic Development Council Funding; RPCI Center for Personalized Medicine established with CTG (NASDAQ: CTGX) serving as its technology partner
Date:1/31/2013

oth quickly and cost-effectively. Those resources, paired with the subject-matter expertise that Dr. Morrison's outstanding team and partners like CTG add to our menu of services, allow us to compete among the small circle of healthcare institutions that have these capabilities," notes Dr. Trump. "The doors are wide open in terms of the opportunities for entrepreneurship and technology transfer that will flow from here."

Senator Timothy Kennedy said, "Roswell Park has long been at the cutting edge of medical advancements in cancer treatment. This strategic investment will not only spur local economic activity, it will also help strengthen Roswell's position as a national leader in cancer research and patient care. The Regional Councils have proven to be vital tools contributing to each region's success. I commend Governor Cuomo for creating these councils, and for the hard work of all the participants to expand this industry in Buffalo."

Assemblywoman Crystal Peoples-Stokes said, "Our Regional Economic Development Council has worked tirelessly to attract business and promote economic growth within the entire region. I congratulate both the council and Roswell Park Cancer Institute for providing much needed revitalization to our community, and applaud Governor Cuomo and Lieutenant Governor Duffy for their hard work and leadership in making this a reality."

Assemblyman Sean Ryan said, "This is excellent news for Erie County. By expanding Roswell Park Cancer Institute, we will not only provide job opportunities for Western New Yorkers, but will also contribute to the overall economic growth of the region. This is another great example of how New York State is supporting creativity and innovation in order to bring jobs to every community in the state, and I thank Governor Cuomo for
'/>"/>

SOURCE Roswell Park Cancer Institute; CTG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. The Acta Materialia Inc Announces New Chairman of the Board of Governors
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / ... on high-single-digit growth in China , as well as solid ... . Europe / Middle East ... sales) showed gains in Germany , Turkey ... +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, on ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... Enhances ... Senior Management Team, ROCKVILLE, Md., June 18 EntreMed, ... the treatment of cancer and inflammatory diseases, today,announced the appointment ... and Business Development. Mr. Bliss has been elected,an executive officer ...
... Access to data may provide potential for label expansion ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today ... Bayer,s phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT ... be appropriate for CTI to begin discussions with the,U.S. ...
... IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), ... guidance for full year 2008,revenue to be in the ... year,2008 earnings per adjusted pro-forma fully diluted share (excluding ... IPO) to be in the,range of $0.87 to $0.94. ...
Cached Biology Technology:EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 2EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 3EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 2IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 3IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Researchers from the Institute of Food Research and The ... a gut bacterium, to help understand how these organisms ... relationship between gut bacteria and the gastrointestinal tract is ... the role of bacteria in establishing and maintaining gut ...
... , Higher temperatures could significantly impact California and other ... next 30 years, according to a new study led ... June 30 edition of Environmental Research Letters , ... land suitable for cultivating premium wine grapes in high-value ...
... BALTIMORE, June 29, 2011 BD Biosciences, a ... today the availability of BD Recharge™, a chemically ... manufacturing that offers productivity comparable to yeast-based peptones. ... significant advance for biopharmaceutical cell culture," said Robert ...
Cached Biology News:Genome analysis will reveal how bacteria in our guts make themselves at home 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 3Global warming could alter the US premium wine industry in 30 years, says Stanford study 4BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2
For microscopy...
... fully automated hybridization of microarrays on slides. ... designed to offer researchers improved reproducibility, superior ... a wide range of applications. Incubations ... denaturations of up to 99C. The possibility ...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Biology Products: